Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsMistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.
A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.
1.
Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.
2.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
3.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
4.
Prostate cancer death risk is higher in late teens and early 20s weight gain.
5.
Gotistobart Response Rate Bests Chemo in Pretreated NSCLC
1.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
2.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
3.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
4.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
5.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Navigating the Complexities of Ph Negative ALL - Part VII
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge